May 31 (Reuters) - Aslan Pharmaceuticals:
* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR ASLAN004 FROM CSL
* ASLAN PHARMACEUTICALS-AMENDED LICENSE AGREEMENT WITH CSL SO CO HAS FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE .COMMERCIALISE ASLAN004 IN ALL INDICATIONS
* ASLAN PHARMACEUTICALS LTD SAYS AMENDED AGREEMENT REPLACES LICENSING AGREEMENT ASLAN AND CSL SIGNED IN MAY 2014
* ASLAN PHARMACEUTICALS-UNDER TERMS OF AMENDED AGREEMENT, CO TO MAKE FIRST PAYMENT OF US$30 MILLION TO CSL UPON COMMENCEMENT OF A PHASE 3 STUDY OF ASLAN004
* ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE UP TO US$95 MILLION OF REGULATORY MILESTONES
* ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE $655 MILLION OF SALES MILESTONES, TIERED ROYALTIES ON NET SALES BETWEEN MID-SINGLE DIGITS AND 10%